Furthermore, the distinct mechanisms of action of PD-1 and CTLA-4 pathway blockade, along with the observed synergistic anti-tumor effects of combined treatment in preclinical models (37–39), led to the clinical evaluation of these two ICIs for cancer patients, demonstrating an enhanced clinical response (40). This evidence concerns the gene PDCD1 and neoplasm.